Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318445 · ClinicalTrials.gov registry record · Phase 1
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
A Phase 1 study, sponsored by Pamela Munster.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03318445 is a Phase 1 study that has completed, run by Pamela Munster. The registered enrollment target is 22 participants.
The verdict
NCT03318445, a Phase 1 study, has completed, sponsored by Pamela Munster.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
Interventions
- DRUG Irinotecan
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2021-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318445
The ClinicalTrials.gov registry entry for NCT03318445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pamela Munster, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT03318445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318445 about?
NCT03318445 is a clinical study titled "Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair". This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
What is the current status of trial NCT03318445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-01-12. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT03318445?
The interventions under investigation include: Irinotecan (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03318445?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.